Toxicity data in addition to survival data are important in evaluating the applicability of a chemotherapy regimen of advanced non-small-cell lung cancer [2]

Lung Cancer

Volumn 49, Issue 2, 2005, Pages 277-

  Hotta, Katsuyuki ^a   Matsuo, Keitaro ^b   Ueoka, Hiroshi ^a  

^a OKAYAMA UNIVERSITY MEDICAL SCHOOL   (Japan)

^b AICHI CANCER CENTER HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; GEMCITABINE; PLATINUM;

ADVANCED CANCER; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; HUMAN; LETTER; LUNG NON SMALL CELL CANCER; META ANALYSIS; PRIORITY JOURNAL; QUALITY OF LIFE; SIDE EFFECT;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; DRUG TOXICITY; HUMANS; LUNG NEOPLASMS; MAXIMUM TOLERATED DOSE;

EID: 22044448622     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2005.01.011     Document Type: Letter

References (3)

1. P.A. Bunn Jr. Chemotherapy for advanced non-small-cell lung cancer: who, what, when, why? J Clin Oncol 20 2002 23S 33S
2. M.Q. Baggstrom, M.A. Socinski, T.A. Hensing, and C. Poole Third generation chemotherapy regimens (3GR) improve survival over second generation regimens (2GR) in stage IIIB/IV non-small cell lung cancer (NSCLC): a meta-analysis of the published literature Proc Am Soc Clin Oncol 21 2002 306a (abstr 1222)
3. T. Le Chevalier, G. Scagliotti, R. Natale, S. Danson, R. Rosell, and R. Stahel Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomes Lung Cancer 47 2005 69 80